Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
2693MO COTESARC: A multicentre, open-label, phase I-II evaluating the combination of MEK and PDL-1 inhibitors in patients with advanced soft tissue sarcoma (STS)
A. Dufresne, M. Brahmi, Claire Cropet, R. Bahleda, Sarah Watson, P. Pautier, I.L. Ray-Coquard, Isabelle Aerts, Axel Le Cesne, Anne Sophie Defachelles, F. Duffaud, G. Garin, M. Bernardin, Cécile Guichard, Laurie Tonon, Cyril Dégletagne, Bertrand Dubois, David Pérol, Jean Yves Blay, N. Corradini (2025). 2693MO COTESARC: A multicentre, open-label, phase I-II evaluating the combination of MEK and PDL-1 inhibitors in patients with advanced soft tissue sarcoma (STS). , 36, DOI: https://doi.org/10.1016/j.annonc.2025.08.3304.
Article20 days agoLBA79 LENVAGIST: A multicentre, comparative, placebo (P)-controlled, double-blinded, phase II study of the efficacy of Lenvatinib (L) in patients with advanced GIST after failure of imatinib and sunitinib
Axel Le Cesne, Claire Cropet, Mehdi Brahmi, Rastislav Bahleda, Emmanuelle Bompas, Thibaud Valentin, Alice Hervieu, Olivier Bouché, Armelle Dufresne, M. Toulmonde, Kévin Bourcier, Florence Duffaud, Marc Pracht, François Bertucci, Loïc Lebellec, Antoîne Italiano, Clémence Hénon, Julien Gautier, David Pérol, Jean Yves Blay (2024). LBA79 LENVAGIST: A multicentre, comparative, placebo (P)-controlled, double-blinded, phase II study of the efficacy of Lenvatinib (L) in patients with advanced GIST after failure of imatinib and sunitinib. , 35, DOI: https://doi.org/10.1016/j.annonc.2024.08.2322.
Article20 days ago59MO COTESARC – A multicentre, phase I-II clinical trial evaluating the combination of MEK and PDL-1 inhibitors in patients (pts) with advanced soft tissue sarcoma (STS): Results from complex (CG) and simple genomic (SG) STS cohorts
Armelle Dufresne, Mehdi Brahmi, Claire Cropet, Rastislav Bahleda, Sarah Watson, Patricia Pautier, I.L. Ray-Coquard, Isabelle Aerts, F. Duffaud, Anne Sophie Defachelles, Benjamin Verret, G. Garin, Cécile Guichard, M. Bernardin, David Pérol, Jean Yves Blay, N. Corradini (2024). 59MO COTESARC – A multicentre, phase I-II clinical trial evaluating the combination of MEK and PDL-1 inhibitors in patients (pts) with advanced soft tissue sarcoma (STS): Results from complex (CG) and simple genomic (SG) STS cohorts. , 9, DOI: https://doi.org/10.1016/j.esmoop.2024.102449.
Article20 days agoLong term activity of vemurafenib in cancers with BRAF mutations: the ACSE basket study for advanced cancers other than BRAFV600-mutated melanoma
Jean Yves Blay, Claire Cropet, Sandrine Mansard, Yohann Loriot, Christelle de la Fouchardière, Julien Haroche, Delphine Topart, David Tougeron, Benoît You, Antoîne Italiano, Valérie Le Brun-Ly, Jean-Marc Ferrero, Nicolas Penel, Michel Fabbro, Xavier Troussard, David Malka, Isabelle Ray‐Coquard, Sophie Leboulleux, Aude Fléchon, E. Maubec, J. Charles, Stéphane Dalle, S. Taïeb, Gabriel Garcia, A.M. Mandache, N. Colignon, Marie Gavrel, F. Nowak, N. Hoog Labouret, Céline Mahier - Aït Oukhatar, Carlos Gomez‐Roca (2023). Long term activity of vemurafenib in cancers with BRAF mutations: the ACSE basket study for advanced cancers other than BRAFV600-mutated melanoma. , 8(6), DOI: https://doi.org/10.1016/j.esmoop.2023.102038.
Article20 days agoREGOMAIN: A randomized, placebo-controlled, double-blinded, multicenter, comparative phase II study of the efficacy of regorafenib as maintenance treatment in patients (pts) with high-grade bone sarcomas (HGBS) at diagnosis or relapse and without complete remission after standard treatment.
Mehdi Brahmi, Julien Gautier, Armelle Dufresne, Perrine Marec‐Bérard, Claire Cropet, Séraphine Vizoso, Laurie Bissuel, Thibaud Valentin, Natacha Entz‐Werlé, Emmanuelle Bompas, Maud Toulmonde, Elsa Kalbacher, Florence Duffaud, Nicolas Penel, Olivier Mir, Justine Gantzer, Pascaline Boudou‐Rouquette, Nelly Firmin, Isabelle Laure Ray-Coquard, Jean Yves Blay (2022). REGOMAIN: A randomized, placebo-controlled, double-blinded, multicenter, comparative phase II study of the efficacy of regorafenib as maintenance treatment in patients (pts) with high-grade bone sarcomas (HGBS) at diagnosis or relapse and without complete remission after standard treatment.. , 40(16_suppl), DOI: https://doi.org/10.1200/jco.2022.40.16_suppl.tps11585.
Article15 days ago